Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.53 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173751 | 0.88 | KDM4E (0.54) | PDK2PDK1PDK3PDK4KDM4E | |
| SCHEMBL12392964 | 0.86 | PDK1 (0.48) | PDK2PDK1PDK3PDK4KDM4E | |
| SCHEMBL3605714 | 0.84 | KDM4E (0.58) | PDK2PDK1PDK3PDK4KDM4E | |
| SCHEMBL19058584 | 0.84 | PDK2 (0.54) | PDK2PDK1PDK3PDK4KDM4E | |
| SCHEMBL377803 | 0.81 | ALDH1A1 (0.62) | KDM4EMAPTGAAMAPK1CA1 | |
| SCHEMBL24842546 | 0.81 | KDM4E (0.55) | PDK2PDK1PDK3PDK4KDM4E | |
| SCHEMBL5440723 | 0.81 | CA12 (0.56) | PDK2PDK1PDK3PDK4KDM4E | |
| SCHEMBL25155623 | 0.78 | KDM4E (0.43) | PDK2PDK1PDK3PDK4KDM4E | |
| SCHEMBL5209585 | 0.78 | KDM4E (0.63) | PDK2PDK1PDK3PDK4KDM4E | |
| SCHEMBL4857497 | 0.78 | KDM4E (0.46) | PDK2PDK1PDK3PDK4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006035308-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20060069087-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2006-03-30 | — | — | US | claimed |
| EP-3634404-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2024-11-20 | — | — | EP | disclosed |
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | ALIVEXIS, INC. (JP) | 2024-03-14 | — | — | US | disclosed |
| CN-111050765-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| CN-110678177-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20070072911-A1 | Indoles and azaindoles as antiviral agents | AVOLIO SALVATORE | 2007-03-29 | — | — | US | disclosed |
| EP-1673081-A1 | INDOLES AND AZAINDOLES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006035308-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069087-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2006-03-30 | — | — | US | disclosed |
| WO-2005034941-A1 | INDOLES AND AZAINDOLES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | PDK2 1125/4885PDK1 795/4885PDK3 855/4885 |
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | TYMS, TYMP, TPMT | PDK2 1370/4885PDK1 1036/4885PDK3 2562/4885 |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | PDK2 796/4885PDK1 723/4885PDK3 1733/4885 |
| US-20060069087-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | PDK2 2919/4885PDK1 2630/4885PDK3 1792/4885 |
| US-20070072911-A1 | Indoles and azaindoles as antiviral agents | IDO1, IDO2, NAT1 | PDK2 3189/4885PDK1 4424/4885PDK3 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.